PaulMSondelMD

Pediatric Hematology & Oncology • Madison, WI

Professor of Pediatrics, University Wisc

Join to view full profile

Dr. Sondel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sondel's full profile

Already have an account?

Office
600 Highland Ave
Madison, WI 53792
Phone+1 608-263-6420

Fax+1 608-263-0440

Education & Training

University of Wisconsin Hospitals and ClinicsResidency, Pediatrics, 1978 - 1980
University of MinnesotaInternship, Pediatrics, 1977 - 1978
Harvard Medical SchoolClass of 1977

Certifications & Licensure

WI State Medical License 1978 - 2025
American Board of Pediatrics Pediatrics

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2002-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Elected Member The American Society for Clinical Investigation, 1988
Whos Who in Medicine and Healthcare Marquis Whos Who
Join now to see all

Clinical Trials

Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors Start of enrollment: 2001 Oct 01
Completed
Phase 1
hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma Start of enrollment: 2005 Aug 01
Completed
Phase 2
N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma Start of enrollment: 2005 Dec 01
Completed
Phase 1
Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma Start of enrollment: 2007 Dec 17
Completed
Phase 2
IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma Start of enrollment: 2020 Jan 30
Suspended
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Ranking antibody binding epitopes and proteins across samples from whole proteome tiled linear peptides.
Sean J McIlwain, Anna Hoefges, Amy K Erbe, Paul M Sondel, Irene M Ong
Bioinformatics. 2024-11-28
1 citations
Intratumoral radiation dose heterogeneity augments antitumor immunity in mice and primes responses to checkpoint blockade.
Justin C Jagodinsky, Jessica M Vera, Won Jong Jin, Amanda G Shea, Paul A Clark
Science Translational Medicine. 2024-09-18
2 citations
Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma.
Mark R Albertini, Cindy L Zuleger, Erik A Ranheim, Oyewale Shiyanbola, Paul M Sondel
Melanoma Research. 2024-08-01

Press Mentions

To Save Children with Cancer, Doctors Turn to New WeaponsAugust 5th, 2022
First-in-Humans Clinical Trial to Treat Children with Relapsed Neuroblastoma Opens at American Family Children’s HospitalNovember 19th, 2020
New Clinical Trial for Advanced Melanoma Patients Seeks to Turn Tumors Against ThemselvesOctober 23rd, 2019
Join now to see all

Grant Support

The Role Of KIR And Fcr Genotype In The Efficacy Of MAB And IL2 ImmunotherapyNational Cancer Institute2012
Antitumor Mechanisms Of Anti-Cd40/Cpg-Activated MacrophagesNational Cancer Institute2008–2011
Clinical Development Of Hu14.18-Il2 Targeted TherapyNational Cancer Institute2006–2011
Phase I Study Of Fenretinide LXS Oral Powder In Patients With NeuroblastomaNational Center For Research Resources2007
Phase II Trial Of Hu1418-Il2 (Emd 273063) In Subjects With Advanced MelanomaNational Center For Research Resources2006–2007
131I-MIBG With Intensive Chemotherapy And Autologous Stem Cell RescueNational Center For Research Resources2006–2007
T-Cell Independent Antitumor Mechanisms Of CD40 LigationNational Cancer Institute2002–2005
Phase I Trial Of Hu14.18-Il-2 In Neuroblastoma And Other Gd2+ TumorsNational Center For Research Resources2004
Clinical Development Of Hu14.18 IL2 Targeted TherapyNational Cancer Institute2000–2004
Phase I Study Of Taxol In Refractory Leukemia In ChildrenNational Center For Research Resources1999–2002
Maintenance Treatment Of Therapy Refractory All W/ B43 PAP ImmunotoxiNational Center For Research Resources1999–2002
Systemic Immunity By Particle Mediated BRM Gene TransferNational Cancer Institute1996–1999
Clinical Testing Of Ch1418-Il2 For Gd2+ TumorsNational Cancer Institute1996–1998
Antibody IL-2 Fusion Protein Delivery By Gene TransferNational Cancer Institute1996–1998
Phase I Trial Of Melanoma Reactive Ch.14.18 PLUS IL2 In Adults With MelanomaNational Center For Research Resources1995–1996
In Vitro Reactivity And Regulation Of Lymphocyte Response In LymphocytesNational Center For Research Resources1995
Combined Modality Antibody Directed Cell CytotoxicityNational Cancer Institute1995
Combined Modality Antibody-Directed Cell CytotoxicityNational Cancer Institute1993–1995
Antitumor Artificial Receptors As Cancer VaccinesNational Cancer Institute1992–1995
Immunobiology Of Antileukemic LymphocytesNational Cancer Institute1994
Clinical Studies Of Biological Response ModifiersDivision Of Cancer Treatment1990–1994
Immunobiology Of Human Antileukemic LymphocytesNational Cancer Institute1990–1993
BRM Monitoring Of Pediatric Neuroblastoma/OsteosarcomaNational Cancer Institute1990–1991
Autologous LAK Cells &Il-2 In Cancer PatientsDivision Of Cancer Treatment1987–1990
The Immunobiology Of Human Antileukemic LymphocytesNational Cancer Institute1985–1989
Clinical Trial Of Natural And Recombinent Interleukin-2Division Of Cancer Treatment1986
Core--Scintillation Counting ServicesNational Cancer Institute1985